Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
EVT-101
Другие языки:

    EVT-101

    Подписчиков: 0, рейтинг: 0
    EVT-101
    EVT-101.svg
    Clinical data
    Other names ENS-101
    Drug class NMDA receptor antagonist
    Identifiers
    • 5-[3-(Difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    Formula C16H13F3N4
    Molar mass 318.303 g·mol−1
    3D model (JSmol)
    • CC1=NC=CN1CC2=NN=CC(=C2)C3=CC(=C(C=C3)F)C(F)F
    • InChI=1S/C16H13F3N4/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19/h2-8,16H,9H2,1H3
    • Key:BOVUHBFXPNLTKF-UHFFFAOYSA-N

    EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder. It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist. The drug was first claimed by Roche in 2002. By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.

    See also



    Новое сообщение